Cep131 overexpression promotes centrosome amplification and colon cancer progression by regulating Plk4 stability.

Cell death & disease (2019-07-31)
Dong Hyun Kim, Jong Seog Ahn, Ho Jin Han, Hye-Min Kim, Joonsung Hwang, Kyung Ho Lee, Hyunjoo Cha-Molstad, In-Ja Ryoo, Jae-Hyuk Jang, Sung-Kyun Ko, Jin Ok Yang, Hee Gu Lee, Sangku Lee, Eun Joo Song, Jin Young Kim, Yang Hoon Huh, Yong Tae Kwon, Nak-Kyun Soung, Bo Yeon Kim

The initiation of centrosome duplication is regulated by the Plk4/STIL/hsSAS-6 axis; however, the involvement of other centrosomal proteins in this process remains unclear. In this study, we demonstrate that Cep131 physically interacts with Plk4 following phosphorylation of residues S21 and T205. Localizing at the centriole, phosphorylated Cep131 has an increased capability to interact with STIL, leading to further activation and stabilization of Plk4 for initiating centrosome duplication. Moreover, we found that Cep131 overexpression resulted in centrosome amplification by excessive recruitment of STIL to the centriole and subsequent stabilization of Plk4, contributing to centrosome amplification. The xenograft mouse model also showed that both centrosome amplification and colon cancer growth were significantly increased by Cep131 overexpression. These findings demonstrate that Cep131 is a novel substrate of Plk4, and that phosphorylation or dysregulated Cep131 overexpression promotes Plk4 stabilization and therefore centrosome amplification, establishing a perspective in understanding a relationship between centrosome amplification and cancer development.

Referencia del producto
Descripción del producto

Monoclonal Anti-γ-Tubulin antibody produced in mouse, clone GTU-88, ascites fluid
Anti-γ-Tubulin antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.